Almac Discovery and Debiopharm International SA, a Switzerland based speciality pharma company, have entered a collaboration for the development of Almac’s Wee-1 kinase inhibitor program.   Almac Discovery has granted exclusive global rights to its Wee-1 patent families and related subject matter expertise to Debiopharm. Almac is eligible to receive an upfront payment and development and commercial milestones, as well as royalties from Debiopharm.   The Wee-1 kinase is a key regulator of a n...